An Interventional Multidisciplinary Approach to Individualize Blood Pressure Treatment (IDA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03209154|
Recruitment Status : Recruiting
First Posted : July 6, 2017
Last Update Posted : April 6, 2018
|Condition or disease||Intervention/treatment||Phase|
|Uncontrolled Hypertension||Diagnostic Test: Therapeutic drug monitoring Device: Home blood pressure monitoring||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Individualized Blood Pressure Treatment: a Multidisciplinary Approach to Uncontrolled Hypertension in Order to Reduce Morbidity and Mortality|
|Actual Study Start Date :||January 30, 2018|
|Estimated Primary Completion Date :||July 31, 2020|
|Estimated Study Completion Date :||July 1, 2022|
Experimental: Study Group
Study Group intervention: Therapeutic drug monitoring.
Diagnostic Test: Therapeutic drug monitoring
Therapeutic drug monitoring will be performed.
Active Comparator: Control Group
Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.
Device: Home blood pressure monitoring
Patients will perform home blood pressure monitoring at home.
- Blood pressure control [ Time Frame: 3 months after baseline ]Change in systolic daytime ambulatory blood pressure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03209154
|Contact: Camilla L Søraas, MD PhDfirstname.lastname@example.org|
|Contact: Sverre E Kjeldsen, MD PhD||+4722119100|
|Oslo University Hospital||Recruiting|
|Oslo, Norway, 0424|
|Contact: Camilla L Søraas, PhD +4799566088 email@example.com|
|Contact: Ulla P Hjørnholm, MSc +4722199338 firstname.lastname@example.org|
|Sub-Investigator: Ola U Bergland, MD|
|Sub-Investigator: Lene V Halvorsen, MD|
|Principal Investigator:||Sverre E Kjeldsen, MD PhD||Oslo University Hospital|